Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. The company is self-described as working to create a people-centered environment.

Arthrosi Therapeutics, Inc.

Arthrosi Therapeutics, Inc. | 596 followers on LinkedIn. Arthrosi is a clinical-stage biotech company focused on developing game-changing therapy for gout and tophaceous gout. | Arthrosi Therapeutics is a leading clinical-stage biotech company dedicated to advancing therapies for gout disease. Our proprietary oral drug candidate, AR882 which is currently in clinical Phase 3, has demonstrated unprecedented sustained urate lowering in gout patients and reduction of tophi, showing exceptional potential to treat millions of patients suffering from gout and tophaceous gout. At Arthrosi Therapeutics, we are committed to transforming the treatment landscape and improving the lives of patients worldwide.

Sr. Director, Clinical Operations at Arthrosi Therapeutics

Liz Polvent

Bioanalytical Scientist

Andrea Clouser Roche

Founder, COO at Arthrosi Therapeutics

Shunqi Yan (颜顺启), Ph.D.

Co-Founder & CEO, Arthrosi Therapeutics, Inc.

Litain Yeh

We’ve just updated our page. Visit us to see the latest updates.

Viewport Meta

IPhone / Mobile Compatible

nginx

Microsoft Exchange Online

DMARC

Office 365 Mail

Google

Google Cloud

Microsoft Azure DNS

Co-Founder & CEO

Founder, COO

Shunqi Yan

Associate Director Quality Assurance

Christy Rodes

Executive Director, Regulatory Affairs and Program Management

Meghan O'Neill

Robert Thomas Keenan

Chief Medical Officer

Founder and COO

Philip Moody

Biotechnology Companies With Fewer Than 50 Employees (Top 10K)

California Companies (Top 10K)

Life Science Companies With Fewer Than 100 Employees

Product Research Companies With Less Than $50M in Revenue

Arthrosi Therapeutics is a biotechnology company that focuses on drug discovery and development.

Venture Round - Arthrosi Therapeutics

Guangrun Health Industry

Series D - Arthrosi Therapeutics

Viva Ventures Biotech Fund

Series C - Arthrosi Therapeutics

Series A - Arthrosi Therapeutics

Laguna Hills

California

United States

North America

Arthrosi Therapeutics

Latest Updates of Viva Biotech's Portfolio Companies

Arthrosi Therapeutics Receives FDA Fast Track Designation for AR882 in Tophaceous Gout

Compounds, compositions and methods for treating or preventing a symptom …

Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study

The Week’s 10 Biggest Funding Rounds: Biotech Dominates As Septerna Raises $150M

Preparation of a compound for the treatment of gout or hyperuricemia

AR882 is a uricosuric drug under development for gout treatment, designed to lower serum urate levels, reduce flares, and resolve tophi, with demonstrated efficacy and safety in clinical trials.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 21, 2024 6:19 AM	713793c7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 21, 2024 6:19 AM	87fd315a
crunchbase trigger	general	Nov 21, 2024 6:19 AM	f4fed426
crunchbase profile	general	Nov 21, 2024 7:24 AM	cfcd98ad
li profile	general	Nov 21, 2024 6:19 AM	c07b1302
translate crunchbase fundingrounds	general	Nov 21, 2024 7:40 AM	8688c0af
peers	general	Nov 21, 2024 6:19 AM	42da94a1
news basic	general	Nov 21, 2024 6:19 AM	f182c808
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ARTH

COM:ARTHROSI

Arthrosi Therapeutics, Inc.